NewG Lab Pharma Launches Official YouTube Channel to "Enhance Communication and Increase Corporate and Pipeline Value"

[Asia Economy Reporter Jang Hyowon] Since the COVID-19 pandemic, the domestic pharmaceutical and bio industry has been actively using YouTube to communicate with investors. In this context, NewgLab Pharma, a company specializing in new drug development, has established a communication channel on YouTube to strengthen communication with shareholders and enhance corporate value.

NewgLab Pharma announced on the 18th that it recently launched an official YouTube channel to strengthen shareholder communication and improve investor understanding amid growing interest in its core pipelines. Through this, NewgLab Pharma plans to share the research and development status and mid- to long-term vision of its new drug candidates under development, thereby raising the awareness of its pipelines and the value of its corporate brand.

The first content uploaded with the channel launch featured Shin Young Han, Executive Director of NewgLab Pharma, who personally appeared to provide a detailed explanation of the mechanism of action and drug value of the anticancer agent KAT, as well as the current industry status related to the pipeline. NewgLab Pharma plans to sequentially upload content that includes the vision of the company’s leap into a comprehensive pharmaceutical and bio company following the acquisition of Arije Pharm and Hanwool TL, including Taletrectinib.

A NewgLab Pharma official said, “Unlike in the past, various platforms such as HTS and MTS have emerged, enhancing investment convenience and greatly expanding the number and base of general investors. NewgLab Pharma established this YouTube channel to respond to the changed IR (Investor Relations) environment and the increased sophistication of general investors.”

He added, “Since the pharmaceutical and bio industry is inherently challenging, we will do our best to provide easy-to-understand and useful high-quality content so that our core pipelines can be properly valued and gain recognition. We will also continuously prepare various measures to maximize the company’s value.”

Meanwhile, NewgLab Pharma is actively conducting Phase 1 and 2a clinical trials of the liver cancer treatment ‘KAT,’ and the research and development achievements of its pipelines are becoming visible, such as the non-small cell lung cancer treatment ‘Taletrectinib’ receiving the FDA’s ‘Breakthrough Therapy Designation (BTD).’